• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Gilead touts Veklury resilience against mutated coronavirus, plots phase 3 for new COVID...

cafead

Administrator
Staff member
  • cafead   Oct 19, 2022 at 11:22: AM
via Gilead Sciences has new data showing COVID drug Veklury maintained efficacy despite changes in a coronavirus structure it targets, just as the company explores expedited ways to launch a pivotal trial for an investigational oral antiviral.

article source